Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURITY study in high-risk resectable biliary tract cancer
2023-503295-25-00Phase 3Authorised
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Jun 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin, gemcitabine, paclitaxel and capecitabine in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer (2 arms), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: 12-month progression-free survival rate. Planned start Jun 2023; status: authorised.
02
Drugs
cisplatingemcitabinepaclitaxelcapecitabine
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on 2023-503295-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503295-25-00.